|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shi Z, Wei Q, Zhang M and She J: MicroRNAs
in bladder cancer: Expression profiles, biological functions,
regulation, and clinical implications. Crit Rev Eukaryot Gene Expr.
24:55–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kou B, Gao Y, Du C, Shi Q, Xu S, Wang CQ,
Wang X, He D and Guo P: miR-145 inhibits invasion of bladder cancer
cells by targeting PAK1. Urol Oncol. 32:846–854. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang K, Wang X, Zou J, Zhang A, Wan Y, Pu
P, Song Z, Qian C, Chen Y, Yang S, et al: miR-92b controls glioma
proliferation and invasion through regulating Wnt/beta-catenin
signaling via Nemo-like kinase. Neuro-oncol. 15:578–588. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu ZB, Cai L, Lin SJ, Lu JL, Yao Y and
Zhou LF: The miR-92b functions as a potential oncogene by targeting
on Smad3 in glioblastomas. Brain Res. 1529:16–25. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Q, Shen K, Zhao Y, Ma C, Liu J and Ma
J: MiR-92b inhibitor promoted glioma cell apoptosis via targeting
DKK3 and blocking the Wnt/beta-catenin signaling pathway. J Transl
Med. 11:3022013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lei L, Huang Y and Gong W: Inhibition of
miR-92b suppresses nonsmall cell lung cancer cells growth and
motility by targeting RECK. Mol Cell Biochem. 387:171–176. 2014.
View Article : Google Scholar
|
|
8
|
Liu Z, Diep C, Mao T, Huang L, Merrill R,
Zhang Z and Peng Y: MicroRNA-92b promotes tumor growth and
activation of NF-κB signaling via regulation of NLK in oral
squamous cell carcinoma. Oncol Rep. 34:2961–2968. 2015.PubMed/NCBI
|
|
9
|
Chen H, Toyooka S, Gazdar AF and Hsieh JT:
Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in
prostate cancer cell lines. J Biol Chem. 278:3121–3130. 2003.
View Article : Google Scholar
|
|
10
|
Shen YJ, Kong ZL, Wan FN, Wang HK, Bian
XJ, Gan HL, Wang CF and Ye DW: Downregulation of DAB2IP results in
cell proliferation and invasion and contributes to unfavorable
outcomes in bladder cancer. Cancer Sci. 105:704–712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu K, Wang B, Chen Y, Zhou J, Huang J, Hui
K, Zeng J, Zhu J, Zhang K, Li L, et al: DAB2IP regulates the
chemoresistance to pirarubicin and tumor recurrence of non-muscle
invasive bladder cancer through STAT3/Twist1/P-glycoprotein
signaling. Cell Signal. 27:2515–2523. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu JN, Wu KJ, Guan ZF, Liu LX, Ning ZY,
Zhou JC, Wang XY and Fan JH: DAB2IP expression in bladder
transitional cell carcinoma and its correlation with clinical
outcome. Sichuan Da Xue Xue Bao Yi Xue Ban. 45:591–594. 2014.In
Chinese. PubMed/NCBI
|
|
13
|
McConkey DJ, Choi W, Marquis L, Martin F,
Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role
of epithelial-to-mesenchymal transition (EMT) in drug sensitivity
and metastasis in bladder cancer. Cancer Metastasis Rev.
28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J and Ma L: MicroRNA control of
epithelial-mesenchymal transition and metastasis. Cancer Metastasis
Rev. 31:653–662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie D, Gore C, Zhou J, Pong RC, Zhang H,
Yu L, Vessella RL, Min W and Hsieh JT: DAB2IP coordinates both
PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc
Natl Acad Sci USA. 106:19878–19883. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu L, Tumati V, Tseng SF, Hsu FM, Kim DN,
Hong D, Hsieh JT, Jacobs C, Kapur P and Saha D: DAB2IP regulates
autophagy in prostate cancer in response to combined treatment of
radiation and a DNA-PKcs inhibitor. Neoplasia. 14:1203–1212. 2012.
View Article : Google Scholar
|
|
18
|
Kong Z, Xie D, Boike T, Raghavan P, Burma
S, Chen DJ, Habib AA, Chakraborty A, Hsieh JT and Saha D:
Downregulation of human DAB2IP gene expression in prostate cancer
cells results in resistance to ionizing radiation. Cancer Res.
70:2829–2839. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie D, Gore C, Liu J, Pong RC, Mason R,
Hao G, Long M, Kabbani W, Yu L, Zhang H, et al: Role of DAB2IP in
modulating epithelial-to-mesenchymal transition and prostate cancer
metastasis. Proc Natl Acad Sci USA. 107:2485–2490. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yun EJ, Baek ST, Xie D, Tseng SF, Dobin T,
Hernandez E, Zhou J, Zhang L, Yang J, Sun H, et al: DAB2IP
regulates cancer stem cell phenotypes through modulating stem cell
factor receptor and ZEB1. Oncogene. 34:2741–2752. 2015. View Article : Google Scholar
|
|
21
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi W, Porten S, Kim S, Willis D, Plimack
ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al:
Identification of distinct basal and luminal subtypes of
muscle-invasive bladder cancer with different sensitivities to
frontline chemotherapy. Cancer Cell. 25:152–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang T, Fan J, Wu K, Zeng J, Sun K, Guan
Z, Wang X, Hiesh JT and He D: Roles of HIF-1α in a novel optical
orthotopic spontaneous metastatic bladder cancer animal model. Urol
Oncol. 30:928–935. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu K, Zeng J, Zhou J, Fan J, Chen Y, Wang
Z, Zhang T, Wang X and He D: Slug contributes to cadherin switch
and malignant progression in muscle-invasive bladder cancer
development. Urol Oncol. 31:1751–1760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu K, Fan J, Zhang L, Ning Z, Zeng J, Zhou
J, Li L, Chen Y, Zhang T, Wang X, et al: PI3K/Akt to
GSK3β/β-catenin signaling cascade coordinates cell colonization for
bladder cancer bone metastasis through regulating ZEB1
transcription. Cell Signal. 24:2273–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blick C, Ramachandran A, Wigfield S,
McCormick R, Jubb A, Buffa FM, Turley H, Knowles MA, Cranston D,
Catto J, et al: Hypoxia regulates FGFR3 expression via HIF-1α and
miR-100 and contributes to cell survival in non-muscle invasive
bladder cancer. Br J Cancer. 109:50–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen H, Pong RC, Wang Z and Hsieh JT:
Differential regulation of the human gene DAB2IP in normal and
malignant prostatic epithelia: Cloning and characterization.
Genomics. 79:573–581. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dote H, Toyooka S, Tsukuda K, Yano M,
Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF, et al:
Aberrant promoter methylation in human DAB2 interactive protein
(hDAB2IP) gene in breast cancer. Clin Cancer Res. 10:2082–2089.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yano M, Toyooka S, Tsukuda K, Dote H,
Ouchida M, Hanabata T, Aoe M, Date H, Gazdar AF and Shimizu N:
Aberrant promoter methylation of human DAB2 interactive protein
(hDAB2IP) gene in lung cancers. Int J Cancer. 113:59–66. 2005.
View Article : Google Scholar
|
|
30
|
Dote H, Toyooka S, Tsukuda K, Yano M, Ota
T, Murakami M, Naito M, Toyota M, Gazdar AF and Shimizu N: Aberrant
promoter methylation in human DAB2 interactive protein (hDAB2IP)
gene in gastrointestinal tumour. Br J Cancer. 92:1117–1125. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Calvisi DF, Ladu S, Conner EA, Seo D,
Hsieh JT, Factor VM and Thorgeirsson SS: Inactivation of Ras
GTPase-activating proteins promotes unrestrained activity of
wild-type Ras in human liver cancer. J Hepatol. 54:311–319. 2011.
View Article : Google Scholar :
|
|
32
|
Duan YF, Li DF, Liu YH, Mei P, Qin YX, Li
LF, Lin QX and Li ZJ: Decreased expression of DAB2IP in pancreatic
cancer with wild-type KRAS. Hepatobiliary Pancreat Dis Int.
12:204–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Smits M, van Rijn S, Hulleman E, Biesmans
D, van Vuurden DG, Kool M, Haberler C, Aronica E, Vandertop WP,
Noske DP, et al: EZH2-regulated DAB2IP is a medulloblastoma tumor
suppressor and a positive marker for survival. Clin Cancer Res.
18:4048–4058. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu Y, He J, Wang Y, Zhu X, Pan Q, Xie Q
and Sun F: miR-889 promotes proliferation of esophageal squamous
cell carcinomas through DAB2IP. FEBS Lett. 589:1127–1135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen H, Tu SW and Hsieh JT:
Down-regulation of human DAB2IP gene expression mediated by
polycomb Ezh2 complex and histone deacetylase in prostate cancer. J
Biol Chem. 280:22437–22444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsai YS, Lai CL, Lai CH, Chang KH, Wu K,
Tseng SF, Fazli L, Gleave M, Xiao G, Gandee L, et al: The role of
homeostatic regulation between tumor suppressor DAB2IP and
oncogenic Skp2 in prostate cancer growth. Oncotarget. 5:6425–6436.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liao H, Xiao Y, Hu Y, Xiao Y, Yin Z and
Liu L: microRNA-32 induces radioresistance by targeting DAB2IP and
regulating autophagy in prostate cancer cells. Oncol Lett.
10:2055–2062. 2015.PubMed/NCBI
|
|
38
|
Haug BH, Henriksen JR, Buechner J, Geerts
D, Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B
and Einvik C: MYCN-regulated miRNA-92 inhibits secretion of the
tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.
Carcinogenesis. 32:1005–1012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li Y, Li L, Guan Y, Liu X, Meng Q and Guo
Q: MiR-92b regulates the cell growth, cisplatin chemosensitivity of
A549 non small cell lung cancer cell line and target PTEN. Biochem
Biophys Res Commun. 440:604–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qian NS, Liu WH, Lv WP, Xiang X, Su M,
Raut V, Chen YL and Dong JH: Upregulated microRNA-92b regulates the
differentiation and proliferation of EpCAM-positive fetal liver
cells by targeting C/EBPß. PLoS One. 8:e680042013. View Article : Google Scholar
|
